Clinical Drug Experience Knowledgebase

Criteria

Inclusion Criteria:

Post-menopausal women aged ≤75.
Signing of ICF.
Willing to and able to correctly complete the urination diary.
Complications of OAB for ≥12 weeks (including: urgent micturition, frequent urination (≥8 times in the daytime, and ≥2 times at the night) and/or urgent urinary incontinence).
No dosing of other drugs of same kind within 14d. -≥8 urination times (24h) in the 1d urination diary.

Exclusion Criteria:

Clinically-significant dysuria(at the investigators' viewpoints).
Serious stress urinary incontinence or mixed stress/urgent urinary incontinence (mainly stress one) confirmed by the investigators.
At the ongoing intubatton or the intermittent self-intubatton.
Evidence-based urinary tract infection or chronic inflammation in the recent 2 weeks (e.g. interstitial cystitis), bladder calculus, past pelvic radiotherapy, and past or existing pelvic malignant tumors.
Uncontrolled narrow-angle glaucoma, urinary/gastric retention, intestinal obstruction and other medical symptoms forbidden for anti-cholinergic drugs at the investigators' viewpoints.
Non-pharmacotherapy (including electrotherapy) or bladder training within 2 weeks before the study initiation (or during the study).
Dosing of diuretics and drugs with the cholinergic or anti-cholinergic adverse reactions
Known or suspicious allergy to Solifenacin Succinate, other anti-cholinergic drugs or lactose.
Clinically-significant symptoms inapplicable for clinical study at the investigators' viewpoints.
Participation in other clinical studies within 30d before the random grouping.
No completion of urination diary according to relevant instructions.
Potentially clinically significant abnormalities (PCSA) inapplicable for clinical study at the investigators' viewpoints.